APA-话题@MedSci

#APA#

153篇内容 | 3647人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1338195, encodeId=7ae41338195ad, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APACHE IV：预测危重症患者预后更为有效, objectType=article, longId=174534, objectId=307e1e453403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=307e1e453403, replyNumber=0, likeNumber=79, createdTime=2019-07-02, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=307e1e453403, moduleTitle=APACHE IV：预测危重症患者预后更为有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=307e1e453403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338194, encodeId=b0c5133819487, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2019 APASL共识建议：慢加急性肝衰竭（更新版）, objectType=article, longId=168427, objectId=976d16842e7f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=976d16842e7f, replyNumber=0, likeNumber=47, createdTime=2019-06-15, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=976d16842e7f, moduleTitle=2019 APASL共识建议：慢加急性肝衰竭（更新版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=976d16842e7f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338193, encodeId=fd2013381937f, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, objectType=article, longId=161873, objectId=c2ee1618e324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ee1618e324, replyNumber=0, likeNumber=53, createdTime=2019-03-09, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ee1618e324, moduleTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ee1618e324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338192, encodeId=d6ad13381923a, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=ARCH PATHOL LAB MED：Papanicolaou试验中低度鳞状上皮内病变与高度鳞状上皮内病变的一致性如何？--来自美国病理学家PAP教育计划的结, objectType=article, longId=159481, objectId=4f9f15948153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f9f15948153, replyNumber=0, likeNumber=67, createdTime=2019-02-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f9f15948153, moduleTitle=ARCH PATHOL LAB MED：Papanicolaou试验中低度鳞状上皮内病变与高度鳞状上皮内病变的一致性如何？--来自美国病理学家PAP教育计划的结, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f9f15948153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338191, encodeId=296513381919a, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=欧盟委员会批准前列腺癌新药Erleada（apalutamide）：口服雄激素受体抑制剂, objectType=article, longId=159087, objectId=b24b15908e2c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b24b15908e2c, replyNumber=0, likeNumber=74, createdTime=2019-01-29, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b24b15908e2c, moduleTitle=欧盟委员会批准前列腺癌新药Erleada（apalutamide）：口服雄激素受体抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b24b15908e2c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338190, encodeId=9a4b133819075, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Galapagos制药旗下骨关节炎药物GLPG1972 / S201086获得FDA快速通道认定, objectType=article, longId=154602, objectId=df4f15460274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df4f15460274, replyNumber=0, likeNumber=89, createdTime=2018-11-30, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df4f15460274, moduleTitle=Galapagos制药旗下骨关节炎药物GLPG1972 / S201086获得FDA快速通道认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df4f15460274)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338189, encodeId=8d00133818951, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=FDA认定rucaparib作为前列腺癌突破性疗法资格, objectType=article, longId=150493, objectId=ac7615049308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac7615049308, replyNumber=0, likeNumber=63, createdTime=2018-10-08, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac7615049308, moduleTitle=FDA认定rucaparib作为前列腺癌突破性疗法资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac7615049308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338188, encodeId=e7ea13381886c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2018 IAP/APA/JPS/EPC指南：慢性胰腺炎截面影像学诊断和严重程度评分, objectType=article, longId=148605, objectId=6e27148605d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e27148605d5, replyNumber=0, likeNumber=39, createdTime=2018-09-12, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e27148605d5, moduleTitle=2018 IAP/APA/JPS/EPC指南：慢性胰腺炎截面影像学诊断和严重程度评分, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e27148605d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338187, encodeId=6fb8133818eed, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=ANN ONCOL：接受niraparib治疗患者的安全性及剂量调整, objectType=article, longId=147479, objectId=99a414e47914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99a414e47914, replyNumber=0, likeNumber=62, createdTime=2018-08-28, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99a414e47914, moduleTitle=ANN ONCOL：接受niraparib治疗患者的安全性及剂量调整, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99a414e47914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338186, encodeId=70f9133818605, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Brit J Cancer：Apatorsen与多烯紫杉醇结合治疗与多烯紫杉醇单独治疗铂抵抗性转移尿路上皮癌的比较研究, objectType=article, longId=140374, objectId=91e81403e4fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91e81403e4fd, replyNumber=0, likeNumber=66, createdTime=2018-06-10, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91e81403e4fd, moduleTitle=Brit J Cancer：Apatorsen与多烯紫杉醇结合治疗与多烯紫杉醇单独治疗铂抵抗性转移尿路上皮癌的比较研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91e81403e4fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338185, encodeId=d55d133818585, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=试验神药Napabucasin肝癌控制率达100%？III期却不容乐观, objectType=article, longId=140285, objectId=fd01140285bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd01140285bb, replyNumber=0, likeNumber=50, createdTime=2018-06-09, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd01140285bb, moduleTitle=试验神药Napabucasin肝癌控制率达100%？III期却不容乐观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd01140285bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338184, encodeId=1c89133818431, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Pharmacogn Mag：Trapa natans可有效对抗抗结核药物引起的肝毒性, objectType=article, longId=138121, objectId=5d21138121af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d21138121af, replyNumber=0, likeNumber=62, createdTime=2018-05-16, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d21138121af, moduleTitle=Pharmacogn Mag：Trapa natans可有效对抗抗结核药物引起的肝毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d21138121af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338183, encodeId=7968133818369, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2018 APAGBI指南：儿童患者围术期静脉血栓栓塞的预防, objectType=article, longId=137095, objectId=a9e813e095f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9e813e095f5, replyNumber=0, likeNumber=0, createdTime=2018-05-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9e813e095f5, moduleTitle=2018 APAGBI指南：儿童患者围术期静脉血栓栓塞的预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9e813e095f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338182, encodeId=660d1338182f9, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=J Laparoendosc Adv Surg Tech A：腹腔镜胆囊切除术后腔内使用罗哌卡因及罗哌卡因-芬太尼合剂镇痛效果的比较：随机、双盲、安慰剂对照试验, objectType=article, longId=135109, objectId=81fa135109f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81fa135109f2, replyNumber=0, likeNumber=62, createdTime=2018-04-14, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81fa135109f2, moduleTitle=J Laparoendosc Adv Surg Tech A：腹腔镜胆囊切除术后腔内使用罗哌卡因及罗哌卡因-芬太尼合剂镇痛效果的比较：随机、双盲、安慰剂对照试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81fa135109f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338181, encodeId=a2a5133818197, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=SGO 2018 | Pembrolizumab联合Niraparib使卵巢癌患者获益, objectType=article, longId=133818, objectId=c2551338183d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2551338183d, replyNumber=0, likeNumber=66, createdTime=2018-03-31, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2551338183d, moduleTitle=SGO 2018 | Pembrolizumab联合Niraparib使卵巢癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2551338183d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338180, encodeId=541f133818076, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL热点丨I-125粒子植入联合TIPS治疗门静脉主干癌栓及其合并症的技术与临床疗, objectType=article, longId=133194, objectId=d354133194dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d354133194dc, replyNumber=0, likeNumber=101, createdTime=2018-03-24, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d354133194dc, moduleTitle=APASL热点丨I-125粒子植入联合TIPS治疗门静脉主干癌栓及其合并症的技术与临床疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d354133194dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338179, encodeId=580a13381e957, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=PAPASH综合征一例, objectType=article, longId=132403, objectId=ecfe132403a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecfe132403a4, replyNumber=0, likeNumber=75, createdTime=2018-03-16, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecfe132403a4, moduleTitle=PAPASH综合征一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecfe132403a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338178, encodeId=fc9513381e874, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Blood：APA和D-二聚体或许可作为无诱因VTE患者复发栓塞的独立的预测因子, objectType=article, longId=131364, objectId=f0981313644a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0981313644a, replyNumber=0, likeNumber=74, createdTime=2018-03-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0981313644a, moduleTitle=Blood：APA和D-二聚体或许可作为无诱因VTE患者复发栓塞的独立的预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0981313644a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338177, encodeId=770413381e753, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2018 APAGE/APSDE实践指南：服用抗栓药物患者接受急诊和择期内镜检查的管理, objectType=article, longId=130245, objectId=052813024545, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=052813024545, replyNumber=0, likeNumber=53, createdTime=2018-02-22, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=052813024545, moduleTitle=2018 APAGE/APSDE实践指南：服用抗栓药物患者接受急诊和择期内镜检查的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=052813024545)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338176, encodeId=140313381e637, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Lancet Gastroen Hepatol：Napabucasin对pSTAT3阳性晚期结肠癌患者表现出良好的治疗效果, objectType=article, longId=128625, objectId=d5d212862558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5d212862558, replyNumber=0, likeNumber=94, createdTime=2018-02-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5d212862558, moduleTitle=Lancet Gastroen Hepatol：Napabucasin对pSTAT3阳性晚期结肠癌患者表现出良好的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5d212862558)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

APA

2020-05-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APACHE IV：预测危重症患者预后更为有效

2019-07-02

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2019 APASL共识建议：慢加急性肝衰竭（更新版）

2019-06-15

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点

2019-03-09

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

ARCH PATHOL LAB MED：Papanicolaou试验中低度鳞状上皮内病变与高度鳞状上皮内病变的一致性如何？--来自美国病理学家PAP教育计划的结

2019-02-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

欧盟委员会批准前列腺癌新药Erleada（apalutamide）：口服雄激素受体抑制剂

2019-01-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Galapagos制药旗下骨关节炎药物GLPG1972 / S201086获得FDA快速通道认定

2018-11-30

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

FDA认定rucaparib作为前列腺癌突破性疗法资格

2018-10-08

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2018 IAP/APA/JPS/EPC指南：慢性胰腺炎截面影像学诊断和严重程度评分

2018-09-12

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

ANN ONCOL：接受niraparib治疗患者的安全性及剂量调整

2018-08-28

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Brit J Cancer：Apatorsen与多烯紫杉醇结合治疗与多烯紫杉醇单独治疗铂抵抗性转移尿路上皮癌的比较研究

2018-06-10

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

试验神药Napabucasin肝癌控制率达100%？III期却不容乐观

2018-06-09

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Pharmacogn Mag：Trapa natans可有效对抗抗结核药物引起的肝毒性

2018-05-16

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2018 APAGBI指南：儿童患者围术期静脉血栓栓塞的预防

2018-05-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

J Laparoendosc Adv Surg Tech A：腹腔镜胆囊切除术后腔内使用罗哌卡因及罗哌卡因-芬太尼合剂镇痛效果的比较：随机、双盲、安慰剂对照试验

2018-04-14

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

SGO 2018 | Pembrolizumab联合Niraparib使卵巢癌患者获益

2018-03-31

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APASL热点丨I-125粒子植入联合TIPS治疗门静脉主干癌栓及其合并症的技术与临床疗

2018-03-24

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

PAPASH综合征一例

2018-03-16

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Blood：APA和D-二聚体或许可作为无诱因VTE患者复发栓塞的独立的预测因子

2018-03-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2018 APAGE/APSDE实践指南：服用抗栓药物患者接受急诊和择期内镜检查的管理

2018-02-22

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Lancet Gastroen Hepatol：Napabucasin对pSTAT3阳性晚期结肠癌患者表现出良好的治疗效果

2018-02-04

科室
- - 订阅+
  - 更多科室
工具
服务